Media Coverage header image

Media Coverage

Advanced Search
  • 10152019
    Markets Insider

    Genealogy giant Ancestry is getting into the business of healthcare. On Tuesday, the company announced two health products: AncestryHealth Core and AncestryHealth Plus, which can help users of the company's DNA test get a sense of their family health history. AncestryHealth Core will cost $149 — or $49 if users have already taken an Ancestry test — while Plus will cost $199, and additional quarterly updates after the first six months will cost $49 fee every six months. Here's what's included in the reports. Visit Business Insider's homepage for more stories. For the first time, family-history website Ancestry will tell you about your genetic health.[CR-LF][CR-LF]Users who have already submitted their spit to Ancestry before don't have to submit a new samples. The products will take about 6-8 weeks to report after ordering, even for those who have already taken the Ancestry test. The company said it plans to have the Plus program available widely in 2020. To perform the next-generation sequencing test, Ancestry's partnering with lab-testing firm Quest Diagnostics.

  • 10072019
    U.S. News & World Report

    More than half of the US.. states and roughly one-third of major U.S. industries saw their rates of workforce drug test positives climb over the past three years – with positives hitting their highest rates in 2018 in more than a decade, according to a series of recent reports from Quest Diagnostics.[CR-LF][CR-LF]Oregon, Maine, Vermont, Alabama, Louisiana and Massachusetts had the highest rates of positive results for urine-based drug tests, according to Quest's analysis of more than 10 million screenings for illicit substances. Across the country, 4.4% of the analyzed drug tests yielded positive results in 2018. In Oregon and Maine, however, more than 6% of the tests were positive last year.

  • 10072019
    HDT: Heavy Duty Trucking Online

    Since 1988, federal regulations have required commercial drivers to submit urine samples for pre-employment, random, and post-accident testing for prohibited drugs.[CR-LF][CR-LF]Twenty years on, the Government Accountability Office (the investigative arm of Congress) published a study outlining serious challenges confronting the Federal Motor Carrier Safety Administration in its oversight of the drug-testing program:[CR-LF][CR-LF]In more than 9% of compliance reviews conducted between 2001 and 2007, carriers had no drug-testing programs at all.Quest Diagnostics reported earlier this year a rise in urine specimens reported as invalid suggest more efforts to cheat.[CR-LF][CR-LF]Drug-testing labs are getting more sophisticated about catching cheaters, but at the same time cheaters are getting smarter about how they try to game the system.

  • 10032019
    Journal Star Online

    Historically low unemployment rates and increasing marijuana use has led some employers in states where recreational cannabis is legal to drop their zero-tolerance policies.[CR-LF][CR-LF]But not everyone is ready to make the leap.[CR-LF][CR-LF]As Illinois readies for recreational marijuana to become legal on Jan. 1, employers here are being told to consider how a zero-tolerance policy may affect their ability to recruit workers.[CR-LF][CR-LF]“Unemployment is so low that employers cannot insist on a zero-tolerance policy,” said Curtis Graves, staff attorney for the Denver-based Employers Council not-for-profit. The council has surveyed Colorado employers every other year since 2014 when recreational use of cannabis was legalized in the state.[CR-LF]Marijuana positivity increased by 75% from 2013 to 2016 in the general U.S. workforce, according to the Quest Diagnostics Drug Testing Index. Nearly 9% tested positive in 2016, according to Quest.

  • 10012019
    Applied Clinical Trials

    Q&A with David Freeman. Most people I talk to in pharma and biotech know that Quest Diagnostics is a leader in laboratory diagnostic services. What they often don’t know is the depth of the company's experience and capabilities in data, analytics and services across the development continuum. Beyond having over 48 billion clinical lab results in its database, Quest has 2,250 patient service centers, increasingly in retail locations, 20,000 mobile care professionals seeing patients in workplaces and the home. Quest provides services to half the country’s hospitals and physicians roughly a third of the adult U.S. population every year. The Clinical Insights portfolio started in 2015 with dialogue between Quest data scientists and medical directors with researchers in pharma who were trying to understand large patterns in disease progression, diagnosis and treatment. Those dialogues, which continue to this day, produce rich insights and customized at-scale data sets and analysis used for research and the planning of new therapeutic launches.